Bli medlem
Bli medlem

Du är här


SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office

SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) has issued an Intention to Grant for the company's European patent application covering AP1189 in methods of treating arthritic diseases.

SynAct has received information that an Intention to Grant has been issued concerning its European patent application 20723141.6 (EP publication 3773558). The European patent, when granted, will provide protection until 2040 for the use of SynAct's lead compound AP1189 in combination with methotrexate in methods of treating arthritic disease, including Rheumatoid Arthritis, as in the recently completed BEGIN study where AP1189 given in combination with methotrexate gave a significant reduction in disease activity. Importantly, the patent application among other also covers the use of combination treatment in other arthritic diseases, such as Psoriatic Arthritis and Ankylosing Spondylitis.

In brief, an "Intention to grant" means that the EPO intends to grant a European patent based on the patent application as currently on file and a final decision to grant will be issued by the EPO when all formalities are adhered to.

 "This is another important step in our construction of a strong and robust portfolio of patents covering AP1189," said SynAct's CSO Thomas Jonassen.  

The information was submitted, through the agency of the contact person below, for publication on December 1, 2021

For further information about SynAct Pharma AB, please contact:  

Jeppe Øvlesen                                    
CEO, SynAct Pharma AB                    
Phone: +45 28 44 75 67                       

Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69

Författare Cision